Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04186546 · ClinicalTrials.gov registry record
Zephyr Valve Registry (ZEVR)
A clinical trial of Emphysema, sponsored by Pulmonx Corporation.
- Active
- Registry status
- 150
- Enrollment target
- 11
- Study locations
NCT04186546 is a study of Emphysema that is active but no longer recruiting, run by Pulmonx Corporation. The registered enrollment target is 150 participants, below the 3,797-participant average among 25 other Emphysema trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT04186546, a study of Emphysema, is active but no longer recruiting, sponsored by Pulmonx Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
Conditions Studied
Interventions
- DEVICE Zephyr Valve Procedure
Study Locations (11)
Pennsylvania
- The Lung Center - DuBois
- University of Pennsylvania - Philadelphia
- Temple University Hospital - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
Illinois
- University of Chicago - Chicago
- Northwestern Medicine - Winfield
Alabama
- University of Alabama at Birmingham - Birmingham
Michigan
- Henry Ford Hospital - Detroit
Texas
- Houston Methodist - Houston
Virginia
- Inova Health - Fairfax
Wisconsin
- Froedtert Memorial-Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04186546
The ClinicalTrials.gov registry entry for NCT04186546 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,797-participant average among 25 other Emphysema trials with a reported enrollment target (96% lower). The listed sponsor is Pulmonx Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Emphysema appearing as the primary indexed condition, and to 1 intervention - of which Zephyr Valve Procedure is the first listed.
NCT04186546 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, Illinois, Alabama.
Frequently Asked Questions
What is clinical trial NCT04186546 about?
NCT04186546 is a clinical study titled "Zephyr Valve Registry (ZEVR)". The purpose of this Post-Approval Registry is to gather ongoing safety and effectiveness assessment of the Zephyr Valve treatment in a real-world setting.
What is the current status of trial NCT04186546?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2019-11-25. Estimated completion is 2026-12-31.
What conditions does trial NCT04186546 study?
This clinical trial studies the following conditions: Emphysema.
What interventions are being tested in trial NCT04186546?
The interventions under investigation include: Zephyr Valve Procedure (DEVICE).
Who is sponsoring clinical trial NCT04186546?
This trial is sponsored by Pulmonx Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04186546 being conducted?
This trial has 11 study locations across Alabama, Illinois, Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Emphysema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COPD Patient-Powered Research Network
RECRUITING
-
Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
RECRUITING
-
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
RECRUITING · NA
-
Implementation of a Sarcopenia Clinic to Diagnose and Treat Skeletal Muscle Loss Due to COPD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.